Latest From Transdermal Ltd.
Dr Reddy's Laboratories Ltd reported robust growth for the second quarter ended September, but plant-related concerns appear to weigh on the firm's near-term prospects.
Radius Health Inc. continues to report positive results for its osteoporosis therapy abaloparatide, but the company's stock has been on a somewhat bumpy ride since results were presented at the recent American Society of Bone and Mineral Research (ASBMR) meeting.
Zosano Pharma Corp. is trading at a fraction of its initial public offering price after the transdermal drug developer revealed that it has parted ways with Eli Lilly & Co. – the second big pharma partnership that the company has lost this year.
Valeant Pharmaceuticals will add a new therapeutic area to its portfolio with the $1bn purchase of Sprout Pharmaceuticals two days after the smaller company won US FDA approval for Addyi (flibanserin) to treat women with a low sex drive, but the Canadian acquirer has some catching up to do with leaders in the female pharma field.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Transdermal Ltd.
- Senior Management
- Anant Pandya, Dev. & Licensing
- Contact Info
Phone: (44) 181 402 9243
37 Limpsfield Road
Sanderstead, CR2 LA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.